Search Result

Results for "

CRC cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (1) Antibiotic (3) Apoptosis (15) Autophagy (3) Bacterial (3) Bcl-2 Family (1) c-Myc (1) Carbonic Anhydrase (2) Casein Kinase (1) CD3 (1) CDK (3) COX (1) CXCR (1) Cytochrome P450 (3) DNA/RNA Synthesis (1) EGFR (1) Endogenous Metabolite (2) ERK (2) Fungal (4) FXR (1) HIF/HIF Prolyl-Hydroxylase (1) HSP (1) LAG-3 (1) MDM-2/p53 (3) Microtubule/Tubulin (3) Mitochondrial Metabolism (1) NF-κB (4) P-glycoprotein (1) Parasite (2) PD-1/PD-L1 (4) PDK-1 (1) PI3K (2) PROTACs (1) Raf (2) Reactive Oxygen Species (2) Somatostatin Receptor (2) STAT (4) STING (1) Topoisomerase (1) Wnt (5) β-catenin (3)
By Research Areas:	Cancer (50) Cardiovascular Disease (1) Infection (9) Inflammation/Immunology (4) Metabolic Disease (1)

By Targets:

Akt (1)

AMPK (1)

Antibiotic (3)

Apoptosis (15)

Autophagy (3)

Bacterial (3)

Bcl-2 Family (1)

c-Myc (1)

Carbonic Anhydrase (2)

Casein Kinase (1)

CD3 (1)

CDK (3)

COX (1)

CXCR (1)

Cytochrome P450 (3)

DNA/RNA Synthesis (1)

EGFR (1)

Endogenous Metabolite (2)

ERK (2)

Fungal (4)

FXR (1)

HIF/HIF Prolyl-Hydroxylase (1)

HSP (1)

LAG-3 (1)

MDM-2/p53 (3)

Microtubule/Tubulin (3)

Mitochondrial Metabolism (1)

NF-κB (4)

P-glycoprotein (1)

Parasite (2)

PD-1/PD-L1 (4)

PDK-1 (1)

PI3K (2)

PROTACs (1)

Raf (2)

Reactive Oxygen Species (2)

Somatostatin Receptor (2)

STAT (4)

STING (1)

Topoisomerase (1)

Wnt (5)

β-catenin (3)

By Research Areas:

Cancer (50)

Cardiovascular Disease (1)

Infection (9)

Inflammation/Immunology (4)

Metabolic Disease (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N5014

Liensinine perchlorate Maximum Cited Publications 10 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
Liensinine Perchlorate is a constituent of?Nelumbo nucifera?Gaertn, with ani-hypertension and anti-cancer activities. Liensinine Perchlorate induces?colorectal cancer (CRC) cell apoptosis .

HY-123772

CDK5 inhibitor 20-223 CP668863	CDK	Cancer
CDK5 inhibitor 20-223 is a potent CDK2 and CDK5 inhibitor with IC₅₀s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent .

HY-155068

FC-116	Reactive Oxygen Species Apoptosis Microtubule/Tubulin	Cancer
FC-11 is a Tubulin inhibitor that effectively inhibits tumor growth in mice. FC-11 can also induce endoplasmic reticulum (ER) stress to generate excess reactive oxygen species (ROS), leading to mitochondrial damage, thereby promoting apoptosis in colorectal cancer (CRC) cells by targeting microtubules. FC-11 can be used in cancer research .

HY-139065

AMPC	Others	Cancer
AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research .

HY-160493

PTK7/β-catenin-IN-6	Wnt β-catenin	Cancer
PTK7/β-catenin-IN-6 (Compound 03653) is an inhibitor for PTK7/β-catenin interaction, which inhibits the Wnt signaling pathway, and exhibits an anticancer activity against colorectal cancer (CRC) .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-P99613

Favezelimab MK-4280	LAG-3	Cancer
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .

HY-B0294

Flubendazole 5+ Cited Publications	Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy	Infection Cancer
Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .

HY-108695

Enterodiol	Apoptosis Endogenous Metabolite	Cancer
Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Anti-cancer activities .

HY-108433

CPT2 Carnitine palmitoyltransferase 2	Apoptosis MDM-2/p53	Metabolic Disease Cancer
CPT2 (Carnitine palmitoyltransferase 2), an enzyme that participates in fatty acid oxidation, also is a colorectal cancer (CRC) prognostic biomarker. CPT2 overexpression can activate p-p53 to increase p53 expression, thereby inhibiting tumor proliferation and promoting apoptosis. CPT2 deficiency results in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Downregulation of CPT2 is also highly correlated with the progression of various cancers and has potential for cancer research .

HY-B0294R

Flubendazole (Standard)	Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy	Infection Cancer
Flubendazole (Standard) is the analytical standard of Flubendazole. This product is intended for research and analytical applications. Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .

HY-151939

BLM-IN-2	DNA/RNA Synthesis Apoptosis	Cancer
BLM-IN-2 is a Bloom's Syndrome Protein (BLM) inhibitor with an IC₅₀ value of 0.8 μM. BLM-IN-2 effectively suppresses the proliferation, invasion, cell cycle arrest and apoptosis of CRC cells. BLM-IN-2 can be used for the reserarch of colorectal cancer (CRC) .

HY-B0008

Sulindac MK-231	NF-κB PD-1/PD-L1	Inflammation/Immunology Cancer
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .

HY-B0008A

Sulindac sodium MK-231 sodium	NF-κB PD-1/PD-L1	Infection Inflammation/Immunology Cancer
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .

HY-N11777

(−)-N-Hydroxyapiosporamide NHAP	NF-κB	Cancer
(−)-N-Hydroxyapiosporamide (NHAP), an alkaloid, is an NF-κB inhibitor with potent antitumor activity in vitro and in vivo. (−)-N-Hydroxyapiosporamide can be used for the research of colorectal cancer (CRC) .

HY-153833

PDS-0330 KVA-E-23A	Others	Cancer
PDS-0330 is a specific and potent Claudin-1 inhibitor. PDS-0330 interferes with claudin-1/Src association and inhibits colorectal cancer (CRC) progression and metastasis .

HY-136541

YB-0158 2 Publications Verification Wnt pathway inhibitor 2	Wnt Apoptosis	Cancer
YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent *colorectal cancer* stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis** in CRC cells. Anti-cancer activities .

HY-108695B

(±)-Enterodiol	Apoptosis Endogenous Metabolite	Cancer
(±)-Enterodiol is the racemate of Enterodiol (HY-108695). Enterodiol is transformed by human intestinal bacteria from lignans contained in various whole-grain cereals, nuts, legumes, flaxseed, and vegetables. Enterodiol has an apoptotic effect in colorectal cancer (CRC) cells. Enterodiol has anti-cancer activities .

HY-B0008R

Sulindac (Standard)	NF-κB PD-1/PD-L1	Inflammation/Immunology Cancer
Sulindac (Standard) is the analytical standard of Sulindac. This product is intended for research and analytical applications. Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer .

HY-162516

DBI-2	AMPK Mitochondrial Metabolism	Cancer
DBI-2 is an AMPK activator targeting mitochondrial complex I. DBI-2 disrupts the OXPHOS process, and reduces ATP generation in mitochondria. DBI-2 inhibits the proliferation of colorectal cancer (CRC) cells .

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-W181530

NCT02	CDK	Cancer
NCT02 is a cyclin K degrader. NCT02 induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. NCT02 has the potential for the research of metastatic colorectal cancer (CRC) .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-114491

Rineterkib	ERK Raf	Cancer
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

HY-114491A

Rineterkib hydrochloride	ERK Raf	Cancer
Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

HY-N3913

Furowanin A	STAT Bcl-2 Family	Cancer
Furowanin A is a flavonoid with anti-neoplastic effects. Furowanin A inhibits STAT3/Mcl-1 axis to suppress proliferation, block cell cycle progression, induce apoptosis and promote autophagy. Furowanin A potently inhibits colorectal cancer (CRC) cells .

HY-161140

PI3Kα-IN-16	PI3K Wnt	Cancer
PI3Kα-IN-16 (Z86) is a novel PI3Kα inhibitor with an IC₅₀ value of 4.28 μM. PI3Kα-IN-16 has potent inhibitory efficiency on PI3K-mediated CRCs growth and migration. PI3Kα-IN-16 also inhibits the Wnt signaling pathway .

HY-158711

STING agonist-38	STING	Cancer
STING agonist-38 (compound 58) is a potent agonist of STING, with the EC₅₀ of 0.05 μM in THP1 cells. STING agonist-38 has certain oral bioactivity .

HY-161970

XSJ05	Topoisomerase Apoptosis	Cancer
XSJ05 is a camptothecin (CPT) derivative that can inhibit topoisomerase I (Topo I) to exert anti-cancer activity. XSJ05 can trigger DNA double-strand breaks, leading to DNA damage. XSJ05 can inhibit the growth of colorectal cancer (CRC), arrest the cell cycle in G2/M phase, and induce apoptosis .

HY-146254

hCAIX-IN-12	Carbonic Anhydrase Apoptosis Reactive Oxygen Species	Cancer
hCAIX-IN-12 is a potent hCAIX inhibitor with IC₅₀ values of 0.74, 10.78 μM for CAIX and CAII, respectively. hCAIX-IN-12 shows antiproliferative effect and induces apoptosis. hCAIX-IN-12 increases ROS production. hCAIX-IN-12 has the potential for the research of colorectal cancer (CRC) .

HY-135103

Tauro-β-muricholic acid sodium 1 Publications Verification T-βMCA sodium	FXR	Cancer
Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC₅₀ of 40 μM .

HY-161102

[Ru(phen)2(xant)] hexafluorophosphate	Autophagy	Cancer
[Ru(phen)2(xant)] hexafluorophosphate is an inducer of Autophagy. [Ru(phen)2(xant)] hexafluorophosphate eliminates CRC stem cells by targeting the chaperone Hsp90. [Ru(phen)2(xant)] hexafluorophosphate reduces cell migration and invasion .

HY-W998345

SMART1	PROTACs PDK-1 Akt	Cancer
SMART1 is a highly specific and CRBN-dependent PROTAC that can effectively degrade Smurf1. SMART1 can block the PDK1-Akt signaling pathway in KRAS mutant colorectal cancer. SMART1 can inhibit tumor growth in KRAS mutant colorectal cancer (CRC) xenograft models.(Blue: CRBN ligand; Black: linker; Pink: Smurf1 ligand (Smurf1-L)) .

HY-161826

Antitumor agent-174	β-catenin HSP CDK c-Myc	Cancer
Antitumor agent-174 (Compound 10) directly engages the N-terminal site of Hsp90 and promotes the degradation of β-catenin, thereby suppressing the Wnt/β-catenin signaling. Antitumor agent-174 effectively inhibits proliferation, induce S and G2/M phases arrest and block the clonogenic ability in CRC cells. Antitumor agent-174 down-regulates CDK1, Cyclin D1, c-Myc, Cyclin B1, and Cyclin A2, and upregulaties P21 proteins. Antitumor agent-174 has significant anti-tumor efficacy against colorectal cancer (CRC) with excellent pharmacokinetics and low toxicity .

HY-129284

APHS	COX	Cancer
APHS is a specific and covalent COX-2 inhibitor with neuroprotective effects. COX-2 is a prostaglandin (PG) synthetase overexpressed in colorectal cancer (CRC) and has pleiotropic cancer-promoting effects. APHS modifies COX-2 by acetylating the active site (serine 516), thereby inhibiting prostaglandin production. The neuroprotective activity of APHS is inhibited by prostaglandin E2. APHS also co-inhibits the WNT pathway, an anti-tumor mechanism in addition to COX-2 inhibition .

HY-161027

DHP-B	Apoptosis	Cancer
DHP-B possesses anti-cancer activity and induces apoptosis. DHP-B covalently binds to Cys96 of CPT1A, blocks FAO, and disrupts the mitochondrial CPT1A-VDAC1 interaction, leading to increased mitochondrial permeability and reduced oxygen consumption and energy metabolism in CRC cells. DHP-B can be isolated from the plant Peperomia dindygulensis .

HY-151628

MRV03-068	Others	Cancer
MRV03-068 (Compound 2) is a selective colibactin-activated peptidase (ClbP) inhibitor that blocks the genotoxic effect of Colibactin (HY-145930) on eukaryotic cells. MRV03-068 can be used in colorectal cancer research .

HY-151629

MRV03-069	Others	Cancer
MRV03-069 (Compound 3) is a selective colibactin-activated peptidase (ClbP) inhibitor that blocks the genotoxic effect of Colibactin (HY-145930) on eukaryotic cells. MRV03-069 can be used in colorectal cancer research .

HY-155391

hCA/Wnt/β-catenin-IN-1	Carbonic Anhydrase P-glycoprotein Wnt β-catenin	Cancer
hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (K_i: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line .

HY-155491

Antibacterial agent 166	Bacterial	Cancer
Antibacterial agent 166 (Compound 19q), a derivative of Nitisinone (HY-B0607), is a selective and orally active *Fusobacterium nucleatum* inhibitor with a MIC₅₀ of 1 μg/mL. Antibacterial agent 166 effectively attenuates the migratory ability of MC-38 cells induced by Fusobacterium nucleatum. Antibacterial agent 166 is a promising anti-F. nucleatum lead compound and can be used for colorectal cancer (CRC) research .

HY-P10596

Lasioglossin-III	Bacterial Fungal	Infection Cancer
Lasioglossin-III is an antimicrobial peptide that can be isolated from the venom of wild bees. Lasioglossin-III has high antibacterial activity against Gram-positive and Gram-negative bacteria, antifungal activity and antitumor activity. Lasioglossin-III has certain cytotoxicity against three cancer cell lines (HeLa S3, CRC SW 480 and CCRF-CEM T) with IC₅₀ values of 4, 18 and 5 μM, respectively .

HY-149558

CXCR4-IN-2	Apoptosis CXCR	Cancer
CXCR4-IN-2 (compound A1) is a bifunctional fluorinated small molecule that is a potent CXCR4 inhibitor with anticancer activity. CXCR4-IN-2 has cytotoxic (IC₅₀: 60 μg/mL; 72 h) and antiproliferative effects on mouse colorectal cancer (CRC) cells. CXCR4-IN-2 induces cell arrest in the G2/M phase and induces apoptosis .

HY-B1324A

Oxiconazole Ro 13-8996 free base	Fungal Cytochrome P450 Antibiotic	Infection Cancer
Oxiconazole (Ro 13-8996) is a broad spectrum anti-fungal agent which can inhibit the growth of Candida, Aspergillus and Trichophyton. Oxiconazole is also a highly efficacious activator of CYP3A4 transactivation, which could be antagonized by Rifampicin (HY-B0272) in a competitive manner. Oxiconazole exhibits inhibitory effect against colorectal cancer (CRC) via peroxiredoxin-2 (PRDX2)-mediated autophagy arrest .

HY-B1324

Oxiconazole nitrate 1 Publications Verification Ro 13-8996	Fungal Cytochrome P450 Antibiotic	Infection Cancer
Oxiconazole (Ro 13-8996) nitrate is a broad spectrum anti-fungal agent which can inhibit the growth of Candida, Aspergillus and Trichophyton. Oxiconazole nitrate is also a highly efficacious activator of CYP3A4 transactivation, which could be antagonized by Rifampicin (HY-B0272) in a competitive manner. Oxiconazole nitrate exhibits inhibitory effect against colorectal cancer (CRC) via peroxiredoxin-2 (PRDX2)-mediated autophagy arrest .

HY-N8146

Bruceantinol	STAT	Infection Cancer
Bruceantinol, a quassinoid isolated from Brucea javanica, inhibits pepper mottle virus in pepper . Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC₅₀=2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and c-Myc .

HY-120675

SSTC3 1 Publications Verification	Casein Kinase Wnt	Cancer
SSTC3 is a casein kinase 1α (CK1α) activator (K_d = 32 nM) that inhibits WNT signaling (EC₅₀ = 30 nM). SSTC3 exhibits minimal gastrointestinal toxicity compared to other classes of WNT inhibitors .

HY-N2187

Deoxyshikonin 1 Publications Verification	Bacterial HIF/HIF Prolyl-Hydroxylase PI3K Apoptosis	Infection Cardiovascular Disease Cancer
Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .

HY-B1324R

Oxiconazole nitrate (Standard)	Fungal Cytochrome P450 Antibiotic	Infection Cancer
Oxiconazole nitrate (Standard) is the analytical standard of Oxiconazole nitrate. This product is intended for research and analytical applications. Oxiconazole (Ro 13-8996) nitrate is a broad spectrum anti-fungal agent which can inhibit the growth of Candida, Aspergillus and Trichophyton. Oxiconazole nitrate is also a highly efficacious activator of CYP3A4 transactivation, which could be antagonized by Rifampicin (HY-B0272) in a competitive manner. Oxiconazole nitrate exhibits inhibitory effect against colorectal cancer (CRC) via peroxiredoxin-2 (PRDX2)-mediated autophagy arrest .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

HY-N12687

Benzosceptrin C	PD-1/PD-L1 Apoptosis	Cancer
Benzosceptrin C is an inhibitor for PD-L1, which promotes programmed cell death ligand (PD-L1) degradation in a lysosomal pathway, enhances the cytotoxicity of T-cells and exhibits antitumor activity .

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library

1,708 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1,708 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-114491

Rineterkib

Fluorescent Dyes/Probes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

Cat. No.	Product Name	Target	Research Area